This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Ocular/ Adnexal Tumors  • Dermatology  • Melanoma  • Alert me on articles by topic

Eric S. Lee, MD; Keith H. Baratz, MD; Jose S. Pulido, MD, MS, MBA; Diva R. Salomão, MD

Arch Ophthalmol. 2006;124:1349-1350.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Uveal melanomas are the most common primary intraocular malignancy in adults. Iris melanomas constitute a small proportion of uveal melanomas with estimates ranging from 4% to 10%.¹ Recent research in tumor microvasculature has emphasized vascular endothelial growth factor (VEGF) as a mediator of tumor angiogenesis. Considering its low metastatic potential (<5%),² iris melanoma may be a good candidate for local therapy using antiangiogenic agents directed against VEGF. To our knowledge, we present the first case of iris melanoma evaluated for VEGF.

Report of a Case

A 68-year-old woman was referred for the evaluation of an iris lesion in the left eye (Figure 1). Three weeks before our evaluation, she developed unilateral decreased vision. On examination, corrected visual acuity was 20/100 with no improvement with pinhole. A small hyphema was present in the anterior chamber. . . . [Full Text of this Article]

Comment

AUTHOR INFORMATION

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Treatment of Iris Melanoma and Secondary Neovascular Glaucoma Using Bevacizumab and Plaque Radiotherapy
Bianciotto et al.
Arch Ophthalmol 2008;126:578-579.
FULL TEXT